RVNC Insider Trading Activity and SEC Form 4 Filings
RVNC insider trading summary
No open-market insider purchases or sales of Revance Therapeutics, Inc. (RVNC) have been reported on SEC Form 4 in the past 12 months.
Latest RVNC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 18, 2024 | David Hollander | CMO & Global Therapeutics Lead | Sell | $16K (3,908 @ $4.17) |
| Apr 16, 2024 | Erica Jordan | Chief Commercial Officer | Sell | $9K (2,392 @ $3.80) |
| Mar 18, 2024 | Dustin S Sjuts | President | Sell | $46K (9,211 @ $5.04) |
| Mar 18, 2024 | Tobin Schilke | CFO | Sell | $47K (9,361 @ $5.04) |
| Mar 18, 2024 | Dwight Moxie | CLO & GC | Sell | $41K (8,125 @ $5.04) |
| Mar 6, 2024 | Mark J Foley | CEO | Buy | $209K (30,000 @ $6.98) |
| Sep 6, 2023 | Dwight Moxie | SVP, GC & Secretary | Sell | $188K (11,000 @ $17.06) |
| Sep 5, 2023 | Dwight Moxie | SVP, GC & Secretary | Sell | $425K (23,853 @ $17.81) |
| Aug 3, 2023 | Mark J Foley | CEO | Sell | $593K (26,279 @ $22.57) |
| Jul 3, 2023 | Mark J Foley | CEO | Sell | $655K (26,279 @ $24.94) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.